Boston's Watchman ups approval chances after warfarin beat
This article was originally published in Clinica
Executive Summary
Boston Scientific’s chances of getting its Watchman left atrial appendage (LAA) closure device approved by the US FDA have improved, after the company presented data showing the device was better than the blood-thinning drug warfarin in preventing cardiovascular death, stroke and embolization.